Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16224
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWilliams, Kathryn H-
dc.contributor.authorSullivan, David R-
dc.contributor.authorNicholson, Geoffrey C-
dc.contributor.authorGeorge, Jacob-
dc.contributor.authorJenkins, Alicia J-
dc.contributor.authorJanuszewski, Andrzej S-
dc.contributor.authorGebski, Val J-
dc.contributor.authorManning, Patrick-
dc.contributor.authorTan, Yong Mong-
dc.contributor.authorDonoghoe, Mark W-
dc.contributor.authorEhnholm, Christian-
dc.contributor.authorYoung, Simon-
dc.contributor.authorO'Brien, Richard C-
dc.contributor.authorBuizen, Luke-
dc.contributor.authorTwigg, Stephen M-
dc.contributor.authorKeech, Anthony C-
dc.date2016-12-21-
dc.date.accessioned2016-09-12T05:27:37Z-
dc.date.available2016-09-12T05:27:37Z-
dc.date.issued2016-05-
dc.identifier.citationMetabolism 2016; 65(5): 783-793en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16224-
dc.description.abstractAIMS: Reported associations between liver enzymes and mortality may not hold true in type 2 diabetes, owing to a high prevalence of non-alcoholic fatty liver disease, which has been linked to cardiovascular disease and mortality in its own right. Our study aimed to determine whether alanine aminotransferase (ALT) or γ-glutamyl transferase (GGT) levels predict mortality in type 2 diabetes, and to examine possible mechanisms. METHODS: Data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study were analyzed to examine the relationship between liver enzymes and all-cause and cause-specific mortality over 5years. RESULTS: Over 5years, 679 (6.9%) individuals died. After adjustment, for every standard deviation increase in ALT (13.2U/L), the HR for death on study was 0.85 (95% CI 0.78-0.93), p<0.001. Conversely, GGT >70U/L, compared with GGT ≤70U/L, had HR 1.82 (1.48-2.24), p<0.001. For cause-specific mortality, lower ALT was associated with a higher risk of cardiovascular death only, whereas GGT >70U/L was associated with higher risks of death due to cardiovascular disease, cancer and non-cancer/non-cardiovascular causes. The relationship for ALT persisted after adjustment for indirect measures of frailty but was attenuated by elevated hsCRP. CONCLUSIONS: As in the general population, ALT has a negative, and GGT a positive, correlation with mortality in type 2 diabetes when ALT is less than two times the upper limit of normal. The relationship for ALT appears specific for death due to cardiovascular disease. Links of low ALT with frailty, as a potential mechanism for relationships seen, were neither supported nor conclusively refuted by our analysis and other factors are also likely to be important in those with type 2 diabetes.en_US
dc.subjectMortalityen_US
dc.subjectAlanine aminotransferaseen_US
dc.subjectγ-Glutamyl transferaseen_US
dc.subjectNon-alcoholic fatty liver diseaseen_US
dc.subjectDiabetes mellitusen_US
dc.titleOpposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleMetabolismen_US
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationSydney Medical School, University of Sydney, Sydney, NSW, Australiaen_US
dc.identifier.affiliationRoyal Prince Alfred Hospital, Sydney, NSW, Australiaen_US
dc.identifier.affiliationNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australiaen_US
dc.identifier.affiliationRural Clinical School, University of Queensland, Brisbane, Queensland, Australiaen_US
dc.identifier.affiliationStorr Liver Unit, Westmead Millennium Institute, Westmead Hospital, Sydney, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Medical and Surgical Sciences, Dunedin School of Medicine, Dunedin, New Zealanden_US
dc.identifier.affiliationTownsville Diabetes and Endocrine Unit, Townsville Hospital, Townsville, Queensland, Australiaen_US
dc.identifier.affiliationBiomedicum Helsinki, Helsinki, Finlanden_US
dc.identifier.affiliationDiabetes Clinic, Northshore Hospital, Auckland, New Zealanden_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27085785en_US
dc.identifier.doi10.1016/j.metabol.2015.12.008en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherO'Brien, Richard C
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptEndocrinology-
crisitem.author.deptUniversity of Melbourne Clinical School-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

26
checked on Dec 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.